SISA 2025 Consensus: High Triglycerides Signal Residual Cardiovascular Risk Even With Controlled LDL

“Recent evidence has confirmed the presence of a clinically relevant residual cardiovascular risk even with low levels of C-LDL.” That warning, from Massimo Grimaldi, president of ANMCO and director of Cardiology at the Miulli Hospital in Acquaviva delle Fonti, frames a question more patients are asking after a routine blood test: why are my triglycerides high when my cholesterol is fine?

The Italian Society for the Study of Atherosclerosis, SISA, addressed exactly that in a consensus document on plasma triglycerides and cardiovascular disease, published in 2025 in the journal Nutrition, Metabolism and Cardiovascular Diseases. Mondosanità reported that the document draws attention to triglyceride-rich lipoproteins and their remnants — particles that can carry cholesterol into artery walls even when measured LDL is well controlled.

That is the concept clinicians call residual risk: the cardiovascular danger that remains after the standard target, LDL cholesterol, has been lowered. Grimaldi made the point at LIPIDS & cardioMETABOLIC CARE, a national ANMCO meeting held in Florence on November 17 and 18 in collaboration with SISA and under the patronage of the American College of Cardiology, CardioInfo reported.

His colleague Federico Nardi, ANMCO’s president-designate and director of Cardiology at Santo Spirito Hospital in Casale Monferrato, told the meeting there is a need for “integrated therapeutic approaches, capable not only of optimising lipid control but also of acting on cardio-nephro-metabolic mechanisms,” according to CardioInfo.

In Plain English: The Clinical Takeaway

  • LDL cholesterol and triglycerides measure different things. A low LDL does not cancel out high triglycerides; the two numbers answer separate questions.
  • Triglycerides rise after meals and respond to excess calories, alcohol, sugar and refined carbohydrates, visceral fat, uncontrolled diabetes and genetic predisposition. Thyroid and kidney problems and some medications can contribute, Mondosanità reported.

What the blood test actually says

Triglycerides are a fuel. After a meal they travel in the blood, then are used or stored. When they stay persistently high, Mondosanità reported, they often show an excess of available energy, a metabolic difficulty in handling it, or a genetic predisposition.

LDL answers a different question: how much cholesterol is sitting inside LDL particles. That is why the report should not be read as a race between a good number and a bad one. Triglyceride-rich particles and their remnants can contribute to arterial disease even when LDL is well controlled.

A single value changes meaning depending on context. Diabetes, hypothyroidism and certain drugs can also modify the result, and while many lipid panels can be done without fasting, the timing of the draw matters for interpretation.

When one number is not enough

The SISA consensus devotes attention to this residual risk, but the decision to look further is individual. In selected patients, Mondosanità reported, two additional measures help: non-HDL cholesterol and apolipoprotein B, or apoB.

Non-HDL cholesterol captures all the cholesterol carried by atherogenic particles, not just LDL. ApoB counts the number of those particles directly, because each one carries a single apoB molecule. Neither is a supplement or a treatment — both are measurements to interpret, Mondosanità stressed, and whether to request them depends on cardiovascular risk, diabetes, family history and the lipid profile, not curiosity about a new number.

Marker What it measures Why it matters here
LDL cholesterol Cholesterol carried inside LDL particles The standard prevention target; often well controlled on statins
Triglycerides Circulating fat, elevated after meals Very high levels raise pancreatitis risk; remnants may be atherogenic
Non-HDL cholesterol Cholesterol in all atherogenic particles Helps clarify residual risk in selected patients
Apolipoprotein B Number of atherogenic particles Shows particle count when LDL alone is not conclusive

Caution on omega-3 capsules

Mondosanità was explicit: do not use omega-3 capsules as a shortcut. Some prescribed formulations have been studied in specific populations; prescribed omega-3s and other drugs come into play when risk and values justify them.

Do not stop statins; prepare questions for your doctor

  • On statin therapy: do not discontinue because LDL has dropped; discuss any change with the prescribing physician first.
  • Before any supplement: do not substitute a capsule for a statin or a treatment indicated for your own risk profile.
  • Bring to the visit: the complete lab report and the list of medications; ask whether the test should be repeated, whether blood glucose or thyroid should be checked, and what an individual target looks like.

At the Florence meeting, Furio Colivicchi, president of the ANMCO Foundation Per il Tuo cuore and director of Clinical and Rehabilitative Cardiology at San Filippo Neri Hospital in Rome, put the challenge plainly: “The current challenge consists not only in reaching ever lower concentrations of cholesterol LDL, but also in addressing the different mechanisms that contribute to residual cardiovascular risk,” he told CardioInfo.

What remains unsettled is how widely apoB and non-HDL testing should spread; the consensus ties them to selected cases rather than routine use. Neither the SISA document nor the meeting coverage discloses funding for the work, and no source in this reporting addresses that question.

The consensus document, led by authors including Alberto Zambon, Luigi Gentile, Federica Galimberti et al., remains the reference point for the discussion that ANMCO and SISA carried into this week’s meeting.

Grimaldi leads an association with a long institutional record: ANMCO, which brings together over 40 scientific societies, was tasked by the Italian National Institute of Health with coordinating Good Clinical Practice recommendations on acute coronary syndromes, presented at its 2026 National Congress. By its own account, over 90 percent of coronary care units in Italy are ANMCO centres.

References

  • Zambon A, Gentile L, Galimberti F, et al. Consensus document on the role of plasma triglycerides in cardiovascular disease from the Italian Society for the Study of Atherosclerosis (SISA). Nutrition, Metabolism and Cardiovascular Diseases, 2025. doi.org/10.1016/j.numecd.2025.104214
  • ACC Expert Consensus Decision Pathway on Persistent Hypertriglyceridemia. JACC, 2021.
  • Mondosanità. “Il colesterolo è basso ma i trigliceridi sono alti: che cosa raccontano gli esami.”
  • CardioInfo. “Dislipidemie, oltre il target LDL: la sfida del rischio cardiovascolare residuo.” CardioInfo

Disclaimer: This article is for information only and does not replace advice from a qualified physician. Interpretation of lipid panels is individual; consult your doctor before changing any therapy.

Photo of author

Health Desk

Health Desk at Archyde.

Toyota Recalls 314,029 Vehicles for Rupture Risk